FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Response:	s)																	
Name and Address of Reporting Person * Niihara Yutaka				2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last) (First) (Middle) 21250 HAWTHORNE BLVD., SUITE 800				3. Date of Earliest Transaction (Month/Day/Year) 10/14/2020								X Officer (give title below) Other (specify below) Chairman and CEO						
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					Line)	
TORRANCE, CA 90503 (City) (State) (Zip)																		
1.Title of Security 2. (Instr. 3) Da		Date	Year) Ex	A. Deemed Execution Date, if ny		if 3	3. Transaction Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities			6. Ownership Form: Direct (D)	7. Nati Indirect Benefit Owner	ct cial ship	
							Code	V	Amoun	or		ce				(I)		.,
stock, \$0.	001 par	10/14/2020					P		1,000	A	\$ 0.8	3	10,708,746	5		D (1)		
Common stock, \$0.001 par value													92,794		I	Intern	national ice,	
Common stock, \$0.001 par value												63,000		I				
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Derivative Conversion Date		tion 3A. D Executy/Year) any	n 3A. Deemed Execution Date, if any		ransacticode	ion	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ons, convertible securi Date Exercisable and Expiration Date Month/Day/Year)		7. A U S (II 4)	. Title and amount of Underlying ecurities (Instr. 3 and) Amount or Number of	8. Price of 9 Derivative I Security (Instr. 5) I I	Deriva Securi Benefi Owned Follow Report Transa	ttive ties cially d ving ted action(s)	Ownership Form of Derivative Security: Direct (D) or Indirect (I)	(Instr. 4)	
	d Address of utaka AWTHOR NCE, CA 9 ecurity stock, \$0. stock, \$0. Report on a s 2. Conversion or Exercise Price of Derivative	d Address of Reporting (utaka) (First) AWTHORNE BLVI (Street) NCE, CA 90503 (State) ecurity stock, \$0.001 par stock, \$0.001 par Report on a separate line 2. Conversion or Exercise Price of Derivative 3. Transact (Month/Da	d Address of Reporting Person (Middle AWTHORNE BLVD., SUITE 8 (Street) NCE, CA 90503 (State) 2. Transaction Date (Month/Day/) stock, \$0.001 par stock, \$0.001 par Stock, \$0.001 par Conversion or Exercise Price of Derivative 3. Transaction Date (Month/Day/Year) Price of Derivative 3. Transaction Date (Month/Day/Year) (Month/Day/Year)	d Address of Reporting Person (Middle) AWTHORNE BLVD., SUITE 800 (Street) NCE, CA 90503 (State) 2. Transaction Date (Month/Day/Year) stock, \$0.001 par 10/14/2020 Stock, \$0.001 par stock, \$0.001 par Table II - I (a.2. Conversion of Exercise Price of Derivative 2. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date any (Month/Day/Year) (Month/Day/Year)	d Address of Reporting Person* (vitaka (First) (Middle) AWTHORNE BLVD., SUITE 800 (10/12 (Street) 4. If A NCE, CA 90503 (State) (Zip) Ecurity 2. Transaction Date (Month/Day/Year) Stock, \$0.001 par 10/14/2020 Stock, \$0.001 par stock, \$0.001 par Report on a separate line for each class of securities be conversion or Exercise Price of Derivative Security (Month/Day/Year) 2. Table II - Derivative Securities of Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	d Address of Reporting Person* (utaka) (First) (Middle) (AWTHORNE BLVD., SUITE 800 (Street) (Street) (State) (Zip) (Cap) (Code (Instr. 8)	d Address of Reporting Person* (First) (Middle) AWTHORNE BLVD., SUITE 800 (Street) 4. If Amendment, (State) (Zip) T. (Month/Day/Year) Stock, \$0.001 par Stock, \$0.001 par Stock, \$0.001 par Conversion or Exercise Price of Derivative Security 2. Issuer Name a Emmaus Life 3. Date of Earlies 10/14/2020 4. If Amendment, 2. A. Deemed Execution Date, if any (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Table II - Derivative Securit (e.g., puts, calls, w (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Exercise (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 8)	Address of Reporting Person* (Intaka (First) (Middle) (Middle) (Middle) (Middle) (Street) (Middle) (Street) (Middle) (Street) (Middle) (Street) (Middle) (M	Code V Stock, \$0.001 par Stock, \$0.001	Code V	Address of Reporting Person - Tutaka (First) (Middle) AWTHORNE BLVD., SUITE 800 (Street) (Street) 2. Issuer Name and Ticker or Trading Symble Emmaus Life Sciences, Inc. [EMMA] 3. Date of Earliest Transaction (Month/Day/Ye) 10/14/2020 4. If Amendment, Date Original Filed/Month/Day (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (A) or Disposed of, (e.g., puts, calls, warrants, options, convertient of Code (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, (e.g., puts, calls, warrants, options, convertient of Code (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, (e.g., puts, calls, warrants, options, convertient of Code (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, (e.g., puts, calls, warrants, options, convertient of Code (Instr. 8) Table II - Derivative Securities Acquired (A) or Disposed of (OD) (Instr. 3, 4, and 5) Date Exercisable Expressable Date Exercisable Date Date Exercisable Date Date Exercisable Date Date Exercisable Date Exercisable Date Date Date Date Date Date Date Dat	Stock, \$0.001 par 10/14/2020 Stock, \$0.001 par Stock, \$0.0	2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]	Address of Reporting Person 2. Issuer Name and Ticker or Trading Symbol Emmans Life Sciences, Inc. [EMMA] WITHORNE BLVD., SUITE 800 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individually Security 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individually Security 2. Transaction Date (Month/Day/Year) 2. Transaction (Month/Day/Year) 3. Transaction (Month/Day/Year) 4. Securities Acquired, Disposed of (D) (Instr. 3) 2. Transaction (Month/Day/Year) 3. Transaction (Month/Day/Year)	Address of Reporting Person* Utaka Cirisr (Visro) (Middle) AWTHORNE BLVD., SUITE 800 AWTHORNE BLVD., SUITE 800 A If Amendment, Date Original FiledMonth/Day/Year) (Street) A If Amendment, Date Original FiledMonth/Day/Year) (Month/Day/Year) (Month/Day/Year) A Securities Acquired, Or or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) A Semities Month Securities Month Securit	Stock, \$0.001 par Code C	Address of Reporting Person 2. Issuer Name and Ticker or Trading Symbol Emmanus Life Sciences, Inc. [EMMA] 5. Relationship of Reporting Person(s) (Check all applicable) Check all applicable)	2. Issuer Name and Ticker or Trading Symbol Emmass Life Sciences, Inc. [EMMA] (Fino) (Addalle) (AWTHORNE BLVD, SUITE 800 (State) (State) (State) (Ap) Table I - Non-Derivative Securities Acquired (Month/Day/Year) (Instr. 3) Amount (Fino) (Month/Day/Year) (Instr. 4) Stock, \$0.001 par 10/14/2020 P 1,000 A

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Niihara Yutaka 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE, CA 90503	X	X	Chairman and CEO				

Signatures

	Yutaka Niihara, M.D., M.P.H.	10/16/2020	
_	**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife.
- (2) Hope International Hospice, Inc, is a California corporation of which Dr. Niihara and his wife are the sole shareholders and directors

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.